Long-term clinical behaviour of jejunoileal involvement in Crohn's disease

被引:19
|
作者
Freeman, HJ [1 ]
机构
[1] Univ British Columbia, Dept Med Gastroenterol, Vancouver, BC V5Z 1M9, Canada
关键词
Crohn's disease; jejunoileitis; nutritional support; small bowel disease; Vienna classification;
D O I
10.1155/2005/647459
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
HJ Freeman. Long-term clinical behaviour of jejunoileal involvement in Crohn's disease. Can J Gastroenterol 2005;19(9):575-578. Diffuse and extensive jejunoileal Crohn's disease is an uncommon entity. In 39 patients, including 21 males and 18 females, followed for a mean duration of over 16 years between 1979 and 2004, the extent of disease was defined and disease behaviour characterized. Over 80% of patients had concomitant colonic and/or gastroduodenal involvement with Crohn's disease, suggesting that this entity may represent a specific clinical phenotype of extensive disease localization. Classification of Crohn's disease behaviour using the Vienna classification schema revealed that virtually all patients in this study suffered from intestinal stricture formation or penetrating disease complications. Moreover, pharmacological therapies with corticosteroids and immunosuppressant drugs were rarely successful, with virtually all patients requiring at least one, and usually multiple, intestinal resections. Finally, most patients required long-term nutritional support, often with home parenteral nutrition. New treatments are required, possibly defined on the basis of their effectiveness in reducing the severity and extent of intestinal disease, rather than more conventional statistically driven reductions in disease activity indexes.
引用
收藏
页码:575 / 578
页数:4
相关论文
共 50 条
  • [31] LONG-TERM FATE OF THE EXCLUDED RECTUM IN CROHN'S DISEASE
    Yzet, Clara
    Kassim, Gasan
    Nair, Nilendra
    Colombel, Jean Frederic
    Sachar, David B.
    GASTROENTEROLOGY, 2019, 156 (06) : S859 - S859
  • [32] Long-term Therapy with Sargramostim in a Patient with Crohn's Disease
    Wong, Alan C.
    Lee, Scott D.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (06) : 1447 - 1448
  • [33] Long-Term Durability of Crohn’s Disease Treatment with Infliximab
    Stephen J. Rudolph
    David I. Weinberg
    Robert P. McCabe
    Digestive Diseases and Sciences, 2008, 53 : 1033 - 1041
  • [34] Long-Term Efficacy of Vedolizumab Therapy for Crohn's Disease
    Hanauer, Stephen
    Rutgeerts, Paul
    Xu, Jing
    Rubin, David
    Smyth, Michael
    Abhyankar, Brihad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S479 - S479
  • [35] Long-term complications in patients with fistulising Crohn's disease
    Vuyyuru, S.
    Kedia, S.
    Sahu, P.
    Bopanna, S.
    Jain, S.
    Makharia, G.
    Ahuja, V.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S271 - S271
  • [36] Understanding Infliximab in Crohn’s Disease: The Long-Term Outcomes
    Dan Turner
    Raffi Lev-Tzion
    Digestive Diseases and Sciences, 2013, 58 : 604 - 607
  • [37] INFLIXIMAB IN CROHN'S DISEASE: LONG-TERM DURABILITY EXPERIENCE
    Dibb, M. J.
    Kemp, K.
    Johnson, C.
    Watson, A.
    Makin, A.
    Campbell, S.
    GUT, 2009, 58 : A94 - A95
  • [38] Long-term outcomes of thalidomide in pediatric Crohn's disease
    Wang, Lin
    Xue, Aijuan
    Zheng, Cuifang
    Zhou, Ying
    Wang, Yuhuan
    Huang, Ying
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (07) : 1124 - 1129
  • [39] Infliximab in Crohn's disease: early and long-term treatment
    Armuzzi, A.
    De Pascalis, B.
    Fedeli, P.
    De Vincentis, F.
    Gasbarrini, A.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 : S271 - S279
  • [40] Methotrexate in Crohn's disease:: long-term efficacy and toxicity
    Lémann, M
    Zenjari, T
    Bouhnik, Y
    Cosnes, J
    Mesnard, B
    Rambaud, JC
    Modigliani, R
    Cortot, A
    Colombel, JF
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (07): : 1730 - 1734